Catalog No.
KAV13402
Description
PRINCIPLE OF THE ASSAY
This assay employs the quantitative indirect enzyme immunoassay technique. Recombinant MPXV A29L antigen has been pre-coated onto a microplate. Standards or samples are pipetted into the wells and any Anti-MPXV A29L Human IgG present is bound by the immobilized protein. After washing away any unbound substances, a biotin-labeled Mouse Anti-Human IgG antibody is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Anti-MPXV A29L Human IgG bound in the initial step. The color development is stopped and the intensity of the color is measured.
Target
A29L
Applications
Used for the quantitative determination of Anti-MPXV A29L Human IgG concentration in serum and plasma.
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
0.63 - 20 ng/mL
Sensitivity
0.42 ng/mL
Precision
Intra-Assay Precision (Precision within an assay): <10%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <15%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
|
|
Intra-Assay Precision
|
Inter-Assay Precision
|
|
Sample
|
1
|
2
|
3
|
1
|
2
|
3
|
|
n
|
16
|
16
|
16
|
24
|
24
|
24
|
|
Mean (ng/mL)
|
8.5
|
2.3
|
1.2
|
9.2
|
2.3
|
1.3
|
|
Standard deviation
|
0.5
|
0.1
|
0.1
|
0.3
|
0.2
|
0.2
|
|
CV (%)
|
5.6
|
5.6
|
6.4
|
3.4
|
6.9
|
12.4
|
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20 ℃, the rest reagents should be store at 4℃.
A Pathogen-Mimicking Monkeypox Virus Nanovaccine Inspired by Assembly of Viral Antigens with β-Glucan and Dendrimer., PMID:40366370
Current status of next-generation vaccines against mpox virus: a scoping review., PMID:40356988
Rational mpox vaccine design: immunogenicity and protective effect of individual and multicomponent proteins in mice., PMID:40105863
Immunogenicity of monkeypox virus surface proteins and cross-reactive antibody responses in vaccinated and infected individuals: implications for vaccine and therapeutic development., PMID:39994775
Chicken-Derived Single-Chain Variable Fragments Targeting Monkeypox Virus A29L Protein., PMID:39989243
Optical biosensing of monkeypox virus using novel recombinant silica-binding proteins for site-directed antibody immobilization., PMID:39850236
Long-Lasting Protection and Dose Optimization of MPXV Polyvalent Mpox mRNA Vaccines Against Lethal Vaccinia Virus Challenge in Mice., PMID:39726255
A penta-component mpox mRNA vaccine induces protective immunity in nonhuman primates., PMID:39639037
Monkeypox virus A29L protein as the target for specific diagnosis and serological analysis., PMID:39570405
Mpox global health emergency: Insights into the virus, immune responses, and advancements in vaccines PART II: Insights into the advancements in vaccines., PMID:39417768
The Generation and Characterization of Monoclonal Antibodies against the MPXV A29L Protein., PMID:39205158
A clinically used anti-human papilloma virus agent (3-hydroxyphthalic anhydride-modified bovine β-lactoglobulin) has a potential for topical application to prevent sexual transmission of monkeypox virus., PMID:39105195
Longitudinal viral shedding and antibody response characteristics of men with acute infection of monkeypox virus: a prospective cohort study., PMID:38802350
Polyvalent mpox mRNA vaccines elicit robust immune responses and confer potent protection against vaccinia virus., PMID:38787725
Levels of antibodies against the monkeypox virus compared by HIV status and historical smallpox vaccinations: a serological study., PMID:38767199
In silico development of a novel anti-mutation, multi-epitope mRNA vaccine against MPXV variants of emerging lineage and sub-lineages by using immunoinformatics approaches., PMID:38450722
Fluorescence-enhanced dual signal lateral flow immunoassay for flexible and ultrasensitive detection of monkeypox virus., PMID:38001482
Development and validation of a highly specific in-house chemiluminescent-based serological assay for the detection of antibodies directed against the human monkeypox virus., PMID:37890729
Evaluation and comparison of immune responses induced by two Mpox mRNA vaccine candidates in mice., PMID:37800627
Cross-reactive antibody response to Monkeypox virus surface proteins in a small proportion of individuals with and without Chinese smallpox vaccination history., PMID:37784185
A Subunit Vaccine Candidate Composed of Mpox Virus A29L, M1R, A35R, and B6R Elicits Robust Immune Response in Mice., PMID:37766097
Duration of humoral immunity from smallpox vaccination and its cross-reaction with Mpox virus., PMID:37709783
Recombinant proteins A29L, M1R, A35R, and B6R vaccination protects mice from mpox virus challenge., PMID:37435062
Mpox virus mRNA-lipid nanoparticle vaccine candidates evoke antibody responses and drive protection against the Vaccinia virus challenge in mice., PMID:37429529
Immunogenic proteins and potential delivery platforms for mpox virus vaccine development: A rapid review., PMID:37353117
Three neutralizing mAbs induced by MPXV A29L protein recognizing different epitopes act synergistically against orthopoxvirus., PMID:37288876
Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus., PMID:37117161
Rational development of multicomponent mRNA vaccine candidates against mpox., PMID:36947428
BoHV-4-Based Vector Single Heterologous Antigen Delivery Protects STAT1(-/-) Mice from Monkeypoxvirus Lethal Challenge., PMID:26086739
For research use only. Not for human or drug use.
